Rho Capital Partners 13F-HR Quarterly holdings report by institutional manager

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE

OMB APPROVAL

OMB Number:		3235-0006
Expires:	Oct 31, 2018
Estimated average burden
hours per response:		23.8

COLUMN 1	COLUMN 2	COLUMN 3	COLUMN 4	COLUMN 5			COLUMN 6	COLUMN 7	COLUMN 8
			VALUE	SHRS OR	SH/	PUT/	INVESTMENT	OTHER	VOTING AUTHORITY
NAME OF ISSUER	TITLE OF CLASS	CUSIP	(x$1000)	PRN AMT	PRN	CALL	DISCRETION	MANAGER	SOLE	SHARED	NONE
CARA THERAPEUTICS INC	COM	140755109	28,502	3,068,057	SH		SOLE		3,068,057	0	0
INOTEK PHARMACEUTICALS CORP	COM	45780V102	16,030	2,627,790	SH		SOLE		2,627,790	0	0
INTRALINKS HLDGS INC	COM	46118H104	85,048	6,290,503	SH		SOLE		6,290,503	0	0
RUBICON PROJ INC	COM	78112V102	380	51,231	SH		SOLE		51,231	0	0
SENSEONICS HLDGS INC	COM	81727U105	562	210,342	SH		SOLE		210,342	0	0